Scientists have used artificial intelligence to develop a new type of vaccine that could provide broad protection against a wide range of viruses and potentially help prevent future pandemics.
A team of researchers from the University of Cambridge confirmed that this is the first time a key component of a vaccine has been fully designed using AI technology and then successfully tested in humans.
The new vaccine is designed to target all coronaviruses, including all existing variants of COVID-19, as well as viruses currently circulating in animals that could potentially jump to humans and cause future global outbreaks.
Unlike traditional vaccines, which are based on the currently active strain of a virus, this new approach uses genetic data from a large number of coronaviruses collected in global virus-tracking databases.
Artificial intelligence analyzed this data and identified common, stable features shared across different viruses. Based on this, the system designed a so-called “superantigen,” which serves as the key component of the vaccine and trains the immune system to recognize a broader range of threats.
According to scientists, this approach could provide protection even when viruses mutate or when new infections emerge from animal sources.
“We are always one step behind viruses. What we are trying to do is get ahead of them — far enough ahead to protect ourselves from entirely new outbreaks or pandemics. This represents a fundamental shift in how we prepare for health crises,” Professor Jonathan Heeney from the University of Cambridge told the BBC.
The first phase of clinical trials was conducted on 39 participants, with the primary goal of testing safety. Results published in the Journal of Infection show that the vaccine is safe for use.
Although the initial immune response was described as modest, scientists remain optimistic and continue further research.
A second trial involving around 200 participants is currently underway to provide more precise data on the strength of the immune response.
Independent experts caution that further large-scale human trials are needed before firm conclusions can be made, noting that the human immune system is far more complex than laboratory models.
However, the scientific community agrees that artificial intelligence represents a major breakthrough that could significantly accelerate the development of new drugs and vaccines, potentially saving millions of lives in the future.
